Brochure
18 Oct 2024

Daewoong Bio Bioplant Promotion Brochure

PDF 10.0 MB

It contains an overall introduction to Daewoong Bio's bio plant's milestones, manufacturing facilities, and production capacity.

Content provided by our supplier

Daewoong Pharmaceutical Co.,Ltd

  • KR
  • 2015
    On CPHI since
  • 1000 - 4999
    Employees
Company types
Manufacturer/Innovator
Pharmaceutical company
Primary activities
Out-licensing specialist
Pharmaceutical Company (generic finished products)
Pharmaceutical Company (innovator finished products)

Other Content from Daewoong Pharmaceutical Co.,Ltd (2)

  • Video DAEWOONG PR VIDEO (EN)

    We continue to take the initiative by making bold challenges and investments in R&D to leap forward as a global healthcare group. Following the 2022 launch of Fexuclue, a drug treating gastroesophageal reflux disease, the company released Envlo, a Type 2 diabetes treatment. By bolstering its R&D pipeline, Daewoong Pharmaceutical is developing first-in-class and best-in-class drugs.